Table 2.

Multivariate cox regression analysis of test and validation cohorts

Cohort	Variable	Hazard Ratio (95% CI)	P Value
A. Glasgow training cohort	Lymph Node Metastases (Positive)	1.92 (1.17-3.15)	0.01
	Tumour size (> 30 mm)	1.48 (1.06-2.06)	0.021
	Tumor Grade (High)	1.77 (1.25-2.52)	0.001
	Resection Margin Involvement (< 1 mm)	1.79 (1.18-2.72)	0.006
	Adjuvant chemotherapy (≥ 3 cycles)	0.54 (0.38-0.77)	0.001
	miR-21 expression (High, HS > 45)	2.11 (1.51-2.96)	< 0.0001
B. Pisa validation cohort	Tumor Stage (T3/T4)	4.47 (1.06-18.9)	0.042
	miR-21 expression (High, HS > 45)	2.03 (1.21-3.39)	0.007
C. Sydney validation cohort	Tumour size (> 30 mm)	2.10 (1.42-3.12)	< 0.0001
	Venous Invasion (Positive)	1.30 (0.98-1.75)	0.070
	Resection Margin Status (Involved, < 1 mm)	1.65 (1.23-2.20)	< 0.0001
	Adjuvant chemotherapy (≥ 3 cycles)	0.59 (0.42-0.86)	0.006
	miR-21 expression (High, HS > 45)	2.59 (1.89-3.53)	< 0.0001
D. ICGC validation cohort	Tumour size (> 30 mm)	2.01 (1.22-3.31)	0.006
	Gender	1.63 (1.04-2.56)	0.032
	Tumour Grade (High)	2.40 (1.41-4.06)	0.001
	Adjuvant chemotherapy (≥ 3 cycles)	0.41 (0.23-0.72)	0.002
	miR-21 expression (High, HS > 45)	2.16 (1.32-3.51)	0.002